Valuation: Alcon

Market Cap 34.03B 29.58B 27.61B 25.35B 47.8B 3,244B 48.63B 326B 128B 1,618B 128B 125B 5,336B P/E 2026 *
32.3x
P/E 2027 * 24.8x
Enterprise Value 36.63B 31.83B 29.72B 27.28B 51.44B 3,491B 52.34B 350B 137B 1,741B 138B 135B 5,742B EV / Sales 2026 *
3.29x
EV / Sales 2027 * 3.01x
Free-Float
97.36%
Yield 2026 *
0.52%
Yield 2027 * 0.59%
Manager TitleAgeSince
Chief Executive Officer 60 30/06/2018
Director of Finance/CFO 58 07/04/2019
Chief Tech/Sci/R&D Officer - 31/12/2024
Director TitleAgeSince
Director/Board Member 60 -
Chairman 70 30/06/2018
Director/Board Member 63 31/01/2019
Change 5-day change 1-year change 3-year change Capi.($)
+13.31%0.00% - - 33.38B
+3.38%+3.73%-33.57%-3.54% 86.73B
+2.64%+5.61%+3.89%-23.83% 14.1B
+1.24%+2.24% - - 10.23B
+7.21%+15.86%-22.78%+573.96% 1.95B
+0.87%+9.56%-35.83%-65.26% 1.52B
+0.70%+11.65%-31.41%-24.61% 891M
+0.52%+4.12%+46.43%-30.11% 808M
+9.88%+7.39%+16.15%+2.59% 771M
+0.67%+8.93% - - 753M
Average +2.74%+5.72%-8.16%+61.31% 13.08B
Weighted average by Cap. +2.50%+1.12%-27.47%+3.13%

Financials

2026 *2027 *
Net sales 11.14B 9.68B 9.04B 8.29B 15.64B 1,061B 15.91B 107B 41.73B 529B 41.83B 40.9B 1,746B 11.81B 10.27B 9.58B 8.8B 16.59B 1,126B 16.88B 113B 44.26B 561B 44.37B 43.38B 1,852B
Net income 1.08B 939M 877M 805M 1.52B 103B 1.54B 10.34B 4.05B 51.37B 4.06B 3.97B 169B 1.35B 1.17B 1.09B 1B 1.89B 128B 1.93B 12.89B 5.05B 64.05B 5.06B 4.95B 211B
Net Debt 2.59B 2.26B 2.11B 1.93B 3.64B 247B 3.71B 24.82B 9.72B 123B 9.75B 9.53B 407B 1.54B 1.34B 1.25B 1.15B 2.16B 147B 2.2B 14.74B 5.77B 73.23B 5.79B 5.66B 242B
Logo Alcon
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.). At the end of 2025, the group operated 17 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA